Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Recruiting in Palo Alto (17 mi)

Overseen byCarlos E. Vargas, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.

Eligibility Criteria

Inclusion Criteria

Age >= 18 years

Planned standard of care curative thoracic RT or CRT with anticipated heart V40 > 20 cc (At least 20 cc of the heart should receive a dose of 40 gray [Gy] or higher)

Able to follow-up at all specified standard of care time-points

+5 more

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Observational (cardiac monitoring)Experimental Treatment4 Interventions

Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.